Leukemia & Lymphoma Society Launches Myeloid Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE LEUKEMIA & LYMPHOMA SOCIETY launched a program to fund research projects focused on myeloid diseases, such as myelodysplastic syndromes and myeloproliferative neoplasms, both of which can progress to acute myeloid leukemia.

Janssen Research & Development is co-sponsoring the program, and together the organizations have committed to providing a combined $1.7 million for the initiative.

LLS is issuing a request for proposals with the intent of funding research projects at $400,000 each for a period of three years. The grants will be administered as part of LLS’s new “Transforming Cures Initiative—Intercepting Progression to Advanced Myeloid Blood Cancers.”

Researchers who apply for these grants will focus on identifying the molecular drivers that cause progression to leukemia and/or working toward development of treatment strategies for early interception of the disease. More information is available at www.lls.org/tci.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login